Novo Nordisk lines up for May Alzheimer's trial

According to database Clinical Trials, Novo Nordisk will launch clinical trials for the company's diabetes drug semaglutide in tablet form as a possible treatment for Alzheimer's in end-May.

Photo: Novo Nordisk / PR

When Novo Nordisk announced in December that it would commence studies with oral semaglutide for treating Alzheimer's, the firm expected that this would happen in the course of the first half-year of 2021.

According to database, Novo Nordisk is now one step closer to starting this process. The firm has registered two studies for the disease, which are currently scheduled to start on May 18.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs